They are not specific in the way they write about the "survival". I’m sure that the idea is that they’re referring to MOS. The trial is supposed to still be under wraps. So they write a general statement which is maybe ballpark:
"Investors are likely to view a survival benefit of 8 months for Abraxane/gemcitabine compared to 6 months for gemcitabine alone as a very positive result."
They are making a subtle suggestion to their readers that they would be smart to buy that CELG stock now. But, just maybe somebody’s setting up a big short on CELG news. And, Motfool suggests that Abraxane could threaten PPHM.
The headline includes the words: “What to Watch”. Magicians like you to watch one hand while the action’s in the other. Maybe someone wants investors to buy that play while somebody else trickle accumulates PPHM. Naw, it couldn’t be!
JMO
sunstar
News 
Market Data 
Discover 
